Please login to the form below

Not currently logged in
Email:
Password:

Gilead EVP, Kevin Young, receives CBE

Kevin Young, executive vice president, Gilead Sciences has been awarded a CBE

Kevin Young, executive vice president, Gilead Sciences has been awarded a CBE "for services to the healthcare and pharmaceutical industries particularly to the development and marketing of life-changing medicines."
 
Young, originally from the north of England, is based at Gilead Sciences in California. Gilead provides the most frequently chosen antiretroviral medicines for the treatment of HIV in the developed world – the life-changing medicines referred to in the CBE citation.

Kevin Young, EVP Gilead Sciences
Kevin Young, EVP Gilead Sciences

 
Gilead's International Access Operations provide these medicines at a no-profit price to almost 100 low-income countries and at sharply discounted prices in a total of 130 developing countries. In total, 2.1 million people worldwide receive one of Gilead's HIV treatments, two thirds (1.4 million) are in the developing world. 

In the UK and Europe, Gilead is well known for Atripla (efavirenz tenofovir emtricitabine): its single tablet regimen (STR) for the treatment of HIV. Atripla is the only single tablet taken once a day that contains the triple-therapy required to successfully control the HIV virus and prevent progression to AIDS.  

13th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics